➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
McKesson
Baxter
Colorcon
Moodys

Last Updated: October 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BGG492


Email this page to a colleague

« Back to Dashboard

Clinical Trials for BGG492

Trial ID Title Status Sponsor Phase Summary
NCT00784212 ↗ Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy Completed Novartis Pharmaceuticals Phase 2 This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.
NCT00887861 ↗ Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery Completed Novartis Phase 2 This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.
NCT00892203 ↗ Efficacy and Safety of BGG492 in the Treatment of Migraine Completed Novartis Phase 2 This study will assess the efficacy and safety of BGG492 used to treat migraine pain.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for BGG492

Condition Name

Condition Name for
Intervention Trials
Partial Onset Seizures 3
Epilepsy 1
Seizures 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Seizures 4
Migraine Disorders 2
Epilepsy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for BGG492

Trials by Country

Trials by Country for
Location Trials
United States 23
Germany 7
Slovakia 4
India 4
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Texas 3
New Jersey 3
Maryland 3
Florida 3
Wisconsin 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for BGG492

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 7
Withdrawn 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for BGG492

Sponsor Name

Sponsor Name for
Sponsor Trials
Novartis Pharmaceuticals 6
Novartis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Baxter
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.